SpeculatingStocks.com Starts Coverage of Stem Cell Stocks for 2009

Pittsburgh, PA (PRWEB) October 15, 2008 -- SpeculatingStocks.com has begun covering stem cell stocks. Watch for stem cell stocks to receive attention in 2009 and become some of the hotter stocks of the year. SpeculatingStocks.com says there are several reasons why stem cell stocks could have a banner year in 2009, but the main one is that the political environment is expected to change in favor of stem cell companies and their research.

Russ Urban of SpeculatingStocks.com (http://www.speculatingstocks.com/) states, "Stem cells are extremely powerful and can dramatically change how we treat various diseases."

There are two kinds of stem cells from animals and humans (embryonic and adult stem cells). Embryonic stem cell research has been a hot topic. A research funding and support bill that came out of Congress under the current Presidency was vetoed.

Several stem cell stocks have been severely oversold and have just begun to move. Stem cell stocks have been severely hampered by policy and lack of funding and support over the past several years.

This has all created an opportunity for stem cell stocks to move big in 2009 and receive a lot of coverage.

There are several stem cell penny stocks that could breakout in 2009. One of the most recognized names in the stem cell small cap stock realm is StemCells, Inc. (Nasdaq: STEM). STEM has a 52-week high of $2.33 and was up $0.05 to $0.99 in Tuesday's trading session from its low of $0.66 on October 10th, 2008.

Another well known name in the stem cell small cap stock space is Geron Corporation (Nasdaq: GERN). GERN (http://www.speculatingstocks.com/Members/StockPicks/GERN%202.html) has a 52-week high of $8.19 and was up $0.11 to $3.04 in Tuesday's trading session from its low of $1.95 on October 10th, 2008.

Stem cell companies are looking for support and they may get that support by way of the next Presidency. It is not a foregone conclusion that the White House will be pro-stem cells under the next Presidency; however, both Senator Barack Obama and Senator John McCain have shown to be pro-stem cells in the past.

Senator Barack Obama, the Democratic Presidential candidate, has released a statement of support for stem cell research on his Senate page. Senator Barack Obama believes we should expand and accelerate research using embryonic stem cells, just as we should continue to explore the viability of adult stem cell use and cord blood use.

Republican Presidential Candidate, Senator John McCain has supported embryonic stem cell research on embryos that would otherwise be discarded during assisted reproduction, but has been receiving pressure from the Republican base to drop support for embryonic stem cell research.

Analysts and investment managers of hedge funds and mutual funds could start investing in stem cell stocks (http://www.speculatingstocks.com/Members/StockUpdates.html) with a possible change in policy on the horizon and the promise held by stem cells.

For more stem cell small cap stocks, take a look at Thermogenesis Corporation (Nasdaq: KOOL), Aastrom Biosciences, Inc. (Nasdaq: ASTM), Cleveland BioLabs, Inc. (Nasdaq: CBLI) and NeoStem, Inc. (AMEX: NBS). View these and other stocks at SpeculatingStocks.com.

About SpeculatingStocks.com:

SpeculatingStocks.com regularly reviews its hundreds of past stock picks. We have been picking stocks since 2004 with a focus on stock picks that create large percentage point returns. For more information, visit SpeculatingStocks.com for stock picks (http://www.speculatingstocks.com/Members/StockPicks.html), stock updates and stock market articles.

Click to join our stock newsletter (http://www.speculatingstocks.com/JoinUs.html).

This press release is the opinion of SpeculatingStocks.com, Inc. SpeculatingStocks.com, Inc. is not a registered investment advisor and nothing contained in any materials released by us should be construed as a recommendation to buy or sell any securities. Please read our legal disclaimer at speculatingstocks.com/LegalDisclaimer.html.

###